login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

FDA clears Trevo Pro Retrieval System to treat acute ischaemic stroke


Tuesday, 14 Aug 2012 10:04
Trevo Pro Retriever
Trevo Pro Retriever

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Stryker for its Trevo Pro Retriever, a clot removal technology designed to treat patients experiencing acute ischaemic stroke.  


The Trevo Pro Retriever demonstrated strong clinical results in the TREVO 2 clinical trial presented at the 2012 European Stroke Conference in May, in Lisbon. This technology demonstrated the highest rate of revascularisation in a randomised embolectomy stroke device trial, and achieved significantly better post-procedure revascularisation than the Merci Retriever (Concentric Medical/Stryker)―92% in the Trevo Retriever arm compared to 76.7% in the Merci Retriever arm.

Other measures of performance also strongly favored the TrevoPro Retriever, including improvement in the National Institutes of Health Stroke Scale (NIHSS) score, excellent composite safety endpoints and shorter hospital stays.


“The launch of this device is another great stride in the evolution of stroke care,” said Gary Duckwiler, TREVO 2 investigator, University of California Los Angeles Medical Center. “Concentric Medical, which is now owned by Stryker, has a long history of partnering with physicians to develop devices specifically designed to remove blood clots from a blocked artery in the brain. The new TrevoPro Retriever is easy to use and very effective at opening blood vessels; allowing physicians to have a significant impact on clinical outcomes.”


“In this patient population, rapidly restoring blood flow to the brain is critical,” said neurologist Wade Smith, University of California San Francisco Medical Center. “This technology advances our ability to help many patients avoid the devastating effects from a large stroke if they can get to a comprehensive stroke centre quickly for treatment.”




Add New Comment

Related Items


Most popular


New device allows brain to bypass spinal cord and move paralysed limbs
Friday, 27 Jun 2014
For the first time ever, a paralysed man has moved his fingers and hand with his own thoughts after an electronic neural bypass for spinal cord injuries that reconnects the brain directly to muscles, ... New device allows brain to bypass spinal cord and move paralysed limbs

FDA IDE approval for PulseRider
Tuesday, 10 Jun 2014
The IDE allows Pulsar Vascular to begin a multicentre clinical trial in support of a humanitarian device exemption (HDE) to evaluate the PulseRider for US approval for wide neck aneurysms at or near ... FDA IDE approval for PulseRider

New insight into how the brain regulates its blood flow
Tuesday, 17 Jun 2014
In a new study published online in the Journal of the American Heart Association, researchers at Columbia Engineering report that they have identified a new component of the biological mechanism that ... New insight into how the brain regulates its blood flow

Features


Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Early brain stimulation may help stroke survivors recover language function
Monday, 21 Jul 2014
Dieter Heiss, who presented on early brain stimulation for stroke patients at the 8th World Congress on Controversies in Neurology (CONy), 8–11 May, Berlin, Germany, writes for NeuroNews on how this ... Early brain stimulation may help stroke survivors recover language function

Profiles


William T Couldwell
Thursday, 24 Apr 2014
William T Couldwell is professor of neurosurgery in the Department of Neurological Surgery, U... William T Couldwell

Ali R Rezai
Monday, 10 Feb 2014
Ali R Rezai speaks to NeuroNews about his clinical and research career, which has been focused on ... Ali R Rezai

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions